Search Results 981-990 of 16416 for monoclonal antibody

  1. A Study of Cell, Serum, and Bone Marrow Bank for Patients receiving Chimeric Antigen Receptor T Cell Therapy for the Treatment of Cancer - Mayo Clinic

    ... antibodies and the factors that may determine disease progression and treatment response. ... Plan to initiate treatment with either bi-specific antibody or CAR-T ...

  2. A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Patients With Kidney Transplant - Mayo Clinic

    To evaluate the efficacy of Cinryze® given for the treatment of acute antibody-mediated rejection (of renal allograft) (AMR) in kidney transplant recipients as ...

  3. Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis - Mayo Clinic

    History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies. ... antibody-forming cells and of T cells into effector ...

  4. Syphilis - Diagnosis and treatment - Mayo Clinic

    The antibodies to the bacteria that causes syphilis stay in the body for years. So blood tests can be used to find a current or past infection. Fluid from a ...

  5. Vanda A. Lennon, M.D., Ph.D. - Mayo Clinic Faculty Profiles

    Mayo Clinic researcher, Vanda A. Lennon, M.D., Ph.D., studies antibodies and autoimmune neurological symptoms in cancer.

  6. Eating during cancer treatment: Tips to make food tastier - Mayo Clinic

    Monoclonal antibody drugs · Mort Crim and Cancer · Mouth sores caused by cancer treatment: How to cope · MRI · Muscle pain · Needle biopsy · Night sweats · No ...

  7. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with Relapsed and Lenalidomide-Refractory Multiple Myeloma - Mayo Clinic

    Serum monoclonal paraprotein (M-protein) level ≥ 1.0 gram per deciliter ... Monoclonal antibody treatment within 21 days. Cytotoxic therapy within 14 ...

  8. Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) - Mayo Clinic

    Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from an adverse event caused by mAbs administered more than 4 ...

  9. Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) - Mayo Clinic

    Previous severe hypersensitivity reaction to another monoclonal antibody (mAb). Active autoimmune disease or a documented history of autoimmune disease or ...

  10. A Study to Evaluate EAA181 to Treat Newly-diagnosed Multiple Myeloma - Mayo Clinic

    ≥ 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis. ... Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease).